Metraipolis › archive › dc_35b46f6cc341

Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group — Europe PMC PMID:42591283

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42591283
DOI
10.3389/fneur.2026.1912200
License (as archived)
solo-consultazione
Archived
2026-10-17T09:49:29.148Z
SHA-256 of the archived text
367b7117d2e0e235bfd4682643fd41449e825a3bb6b228c29b3d13e0f47ebad6
Stable URL of this page
https://metraipolis.com/documento/dc_35b46f6cc341

How to cite

Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group — Europe PMC PMID:42591283 — Europe PMC (en), https://europepmc.org/article/MED/42591283 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_35b46f6cc341 (Metraipolis archive dc_35b46f6cc341, sha256 367b7117d2e0e235bfd4682643fd41449e825a3bb6b228c29b3d13e0f47ebad6)
BibTeX
@misc{dc35b46f6cc341,
  title = {Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group — Europe PMC PMID:42591283},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42591283},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_35b46f6cc341; sha256 367b7117d2e0e235bfd4682643fd41449e825a3bb6b228c29b3d13e0f47ebad6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42591283. Agents can read the archived copy with the MCP tool read_document.